A Mutation Conferring Resistance to Imatinib at the Time of Diagnosis of Chronic Myelogenous Leukemia
- 29 May 2003
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 348 (22) , 2265-2266
- https://doi.org/10.1056/nejmc035089
Abstract
Acquired resistance to imatinib mesylate caused by kinase-domain mutations is common in patients with chronic myelogenous leukemia who are treated with the drug.1 Until now, such mutations have been reported only at the time of clinically apparent resistance or relapse.2,3 We describe a patient with chronic myelogenous leukemia in whom a minor population of imatinib-resistant cells were present at the time of diagnosis.Keywords
This publication has 3 references indexed in Scilit:
- Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatmentBlood, 2002
- Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemiaCancer Cell, 2002
- Molecular mechanisms of resistance to STI571 in chronic myeloid leukemiaCurrent Opinion in Hematology, 2002